Telix heads to the US, as RayzeBio runs into problems
Supply continues to cause headaches for radiopharmaceutical developers.
Verastem spoils its ASCO bounce
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
